Caspofungin

CHEMBL1630575 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1093.3 g/mol

LogP

0.3

Phase

4

An antifungal agent belonging to the echinocandin class that inhibits the synthesis of beta-1,3-D-glucan, an essential component of the fungal cell wall not found in human cells. It is used intravenously to treat invasive Aspergillus and Candida infections in patients who are unresponsive to or intolerant of other antifungals. Its targeted mechanism results in a favorable tolerability profile compared to older antifungals.

Molekularmasse

1093,3000 g/mol

LogP

0,30

TPSA

412,00 Å²

Lipinski-Regel der Fünf

Nicht bestanden

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Non-Alcoholic Fatty Liver Disease Obesity Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O

InChI

InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28-,29+,30+,33+,34-,35-,36+,37-,38+,40-,41-,42-,43-,44-,45-,46-/m0/s1

Molecular Formula

C52H88N10O15

HBD / HBA

16 / 18

Rotierbare Bindungen

23

Schwere Atome

77

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

An antifungal agent belonging to the echinocandin class that inhibits the synthesis of beta-1,3-D-glucan, an essential component of the fungal cell wall not found in human cells. It is used intravenously to treat invasive Aspergillus and Candida infections in patients who are unresponsive to or intolerant of other antifungals. Its targeted mechanism results in a favorable tolerability profile compared to older antifungals.

Yes, Caspofungin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1630575. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 16119814. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Caspofungin auf PillFYI

Struktur

Schnelldaten

Formel: C52H88N10O15
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.